ArticleBioinformatics (Oxford, England)2026
VCCV: conservative transcriptomic corroboration for measurement prioritization of computational drug-target hypotheses.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
motivationComputational drug-target interaction (DTI) models nominate plausible binders but cannot determine which candidate best accounts for an observed cellular response. Perturbational transcriptomics offers orthogonal mechanistic evidence, yet pharmacology-to-genetics mismatch, incomplete reference coverage, and non-specific stress programs make simple signature matching unreliable. This motivates a principled integration layer that corroborates hypotheses conservatively, abstains under global mismatch, and prioritizes informative follow-up measurements when the evidence remains ambiguous.
resultsWe present Virtual-to-Cellular Corroboration for Validation (VCCV), a model-agnostic posterior-triage layer for pre-trained DTI models. VCCV updates calibrated DTI working weights with context-aligned perturbational evidence using a near-identity affine map and exact covariance transport. Within the stated Gaussian class, exact transport is the unique uncertainty update that preserves posterior-odds comparisons under invertible affine changes of measurement coordinates. VCCV also introduces an empirical warning branch for abstention and converts residual ambiguity into compact follow-up gene panels, using a submodular objective for deep near-ties. Each query is assigned one of three actionable states: a target-resolved hypothesis, an abstention, or a prioritized panel. Across five DTI models, VCCV improved discrimination (paired ROC-AUC gains 0.021-0.037) and reduced negative log-likelihood in every case. Additional evaluations showed improved ranking on the same-cell-supported endpoint, warning-score discrimination of strong-response profiles (ROC-AUC 0.876), and better recovery of full-coordinate leading hypotheses by selected panels than by random panels. Across these retrospective kinase-focused evaluations, VCCV provides a principled bridge from computational nomination to conservative, measurement-directed cellular corroboration. AVAILABILITY AND IMPLEMENTATION: Source code of VCCV is publicly available at https://github.com/bio-ai-source/VCCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.